IL178672A0 - Imidazole derivatives used as tafia inhibitors - Google Patents

Imidazole derivatives used as tafia inhibitors

Info

Publication number
IL178672A0
IL178672A0 IL178672A IL17867206A IL178672A0 IL 178672 A0 IL178672 A0 IL 178672A0 IL 178672 A IL178672 A IL 178672A IL 17867206 A IL17867206 A IL 17867206A IL 178672 A0 IL178672 A0 IL 178672A0
Authority
IL
Israel
Prior art keywords
imidazole derivatives
derivatives used
tafia inhibitors
tafia
inhibitors
Prior art date
Application number
IL178672A
Other versions
IL178672A (en
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34964308&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL178672(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of IL178672A0 publication Critical patent/IL178672A0/en
Publication of IL178672A publication Critical patent/IL178672A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL178672A 2004-04-22 2006-10-17 Imidazole derivatives used as tafia inhibitors IL178672A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004020186A DE102004020186A1 (en) 2004-04-22 2004-04-22 Heterocyclyl acetic acids as inhibitors of TAFla
PCT/EP2005/003630 WO2005105781A1 (en) 2004-04-22 2005-04-07 Imidazole derivatives used as tafia inhibitors

Publications (2)

Publication Number Publication Date
IL178672A0 true IL178672A0 (en) 2007-02-11
IL178672A IL178672A (en) 2011-08-31

Family

ID=34964308

Family Applications (1)

Application Number Title Priority Date Filing Date
IL178672A IL178672A (en) 2004-04-22 2006-10-17 Imidazole derivatives used as tafia inhibitors

Country Status (35)

Country Link
EP (2) EP1864979B1 (en)
JP (1) JP4939401B2 (en)
KR (1) KR101162047B1 (en)
CN (1) CN100572376C (en)
AR (1) AR053302A1 (en)
AT (2) ATE386737T1 (en)
AU (1) AU2005238144B2 (en)
BR (1) BRPI0510159A (en)
CA (1) CA2563401C (en)
CR (1) CR8650A (en)
CY (1) CY1108087T1 (en)
DE (2) DE102004020186A1 (en)
DK (1) DK1740569T3 (en)
EC (1) ECSP066941A (en)
ES (1) ES2299026T3 (en)
HK (1) HK1101823A1 (en)
HR (1) HRP20080099T3 (en)
IL (1) IL178672A (en)
MA (1) MA28543B1 (en)
MY (1) MY140903A (en)
NI (1) NI200600217A (en)
NO (1) NO20065320L (en)
NZ (1) NZ550757A (en)
PE (1) PE20060172A1 (en)
PL (1) PL1740569T3 (en)
PT (1) PT1740569E (en)
RS (1) RS50553B (en)
RU (1) RU2375356C2 (en)
SI (1) SI1740569T1 (en)
TN (1) TNSN06341A1 (en)
TW (1) TWI359016B (en)
UA (1) UA87306C2 (en)
UY (1) UY28868A1 (en)
WO (1) WO2005105781A1 (en)
ZA (1) ZA200607668B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090087044A (en) * 2006-12-06 2009-08-14 사노피-아벤티스 Urea and sulfamide derivatives as tafia inhibitors
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
JP2010518161A (en) * 2007-02-13 2010-05-27 シェーリング コーポレイション Chroman derivatives and analogs as function selective α2C adrenergic receptor agonists
AU2008279447A1 (en) * 2007-07-19 2009-01-29 Metabolex, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders
WO2009103432A2 (en) * 2008-02-21 2009-08-27 Sanofi-Aventis Covalently binding imaging probes
JP5531011B2 (en) * 2008-06-06 2014-06-25 サノフイ Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIa
WO2010050525A1 (en) 2008-10-29 2010-05-06 大正製薬株式会社 Compound having tafia inhibitory activity
KR20120016651A (en) 2009-05-15 2012-02-24 사노피 Process for the preparation of a compound useful as an inhibitor of tafia
FR2947266B1 (en) * 2009-06-26 2011-06-17 Servier Lab NOVEL 2-MERCAPTOCYCLOPENTANECARBOXYLIC ACID DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
US8410127B2 (en) 2009-10-01 2013-04-02 Metabolex, Inc. Substituted tetrazol-1-yl-phenoxymethyl-thiazol-2-yl-piperidinyl-pyrimidine salts
KR20130006620A (en) 2010-03-18 2013-01-17 다이이찌 산쿄 가부시키가이샤 Cyclopropanecarboxylic acid derivative
RU2572814C2 (en) 2010-03-18 2016-01-20 Дайити Санкио Компани, Лимитед CYCLOALKYL-SUBSTITUTED IMIDAZOLE DERIVATIVE, POSSESSING INHIBITING ACTIVITY WITH RESPECT TO TAFIa
AU2011328263A1 (en) 2010-11-11 2013-05-30 Sanofi Process for the preparation of 3-(6-amino-pyridin-3yl)-2-acrylic acid derivatives
US9145385B2 (en) 2011-11-25 2015-09-29 Sanofi Crystalline salts of R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexy1-1H-imidazol-4-yl)-propionic acid
US9102657B2 (en) * 2011-11-25 2015-08-11 Sanofi Sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1H-imidazol-4-yl)-propionic acid
WO2013076177A1 (en) 2011-11-25 2013-05-30 Sanofi Salt of (r)-3-(6-amino-pyridin-3-yl)-2-(1-cyclohexyl-1h-imidazol-4-yl) ethyl propionate
EP2805705B1 (en) 2013-05-23 2016-11-09 IP Gesellschaft für Management mbH Packaging with one or more administration units comprising a sodium salt of (R)-3-[6-amino-pyridin-3-yl]-2-(1-cyclohexyl-1 H-imidazol-4-yl)-propionic acid
RU2015156612A (en) * 2013-06-10 2017-07-17 Санофи MACROCYCLIC DERIVATIVES OF UREA AS TAFIA INHIBITORS, THEIR PRODUCTION AND USE thereof AS PHARMACEUTICAL PRODUCTS
WO2017170460A1 (en) 2016-03-29 2017-10-05 第一三共株式会社 Inflammatory intestinal disease therapeutic agent
WO2018026890A1 (en) 2016-08-03 2018-02-08 Cymabay Therapeutics Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003013526A1 (en) * 2001-08-08 2003-02-20 Merck & Co. Inc. Anticoagulant compounds
BR0307033A (en) 2002-01-22 2004-12-07 Pfizer 3- (imidazolyl) -2-aminopropanoic acids for use as tafi-a inhibitors for the treatment of thrombotic diseases

Also Published As

Publication number Publication date
KR101162047B1 (en) 2012-07-04
ES2299026T3 (en) 2008-05-16
JP2007533672A (en) 2007-11-22
KR20070007346A (en) 2007-01-15
TNSN06341A1 (en) 2008-02-22
RU2375356C2 (en) 2009-12-10
CN1950357A (en) 2007-04-18
CN100572376C (en) 2009-12-23
HRP20080099T3 (en) 2008-03-31
PL1740569T3 (en) 2008-07-31
UY28868A1 (en) 2005-11-30
PE20060172A1 (en) 2006-03-31
SI1740569T1 (en) 2008-06-30
AU2005238144A1 (en) 2005-11-10
JP4939401B2 (en) 2012-05-23
CY1108087T1 (en) 2014-02-12
RU2006141246A (en) 2008-06-10
IL178672A (en) 2011-08-31
WO2005105781A1 (en) 2005-11-10
RS50553B (en) 2010-05-07
NO20065320L (en) 2007-01-12
CR8650A (en) 2007-12-04
TWI359016B (en) 2012-03-01
HK1101823A1 (en) 2007-10-26
PT1740569E (en) 2008-03-31
BRPI0510159A (en) 2007-10-02
EP1740569B1 (en) 2008-02-20
ATE523505T1 (en) 2011-09-15
ZA200607668B (en) 2008-03-26
TW200602325A (en) 2006-01-16
DK1740569T3 (en) 2008-06-02
NI200600217A (en) 2008-06-17
CA2563401C (en) 2012-08-07
DE502005002927D1 (en) 2008-04-03
ECSP066941A (en) 2006-12-20
NZ550757A (en) 2010-06-25
EP1740569A1 (en) 2007-01-10
MA28543B1 (en) 2007-04-03
AR053302A1 (en) 2007-05-02
EP1864979A1 (en) 2007-12-12
AU2005238144B2 (en) 2010-08-26
UA87306C2 (en) 2009-07-10
MY140903A (en) 2010-01-29
DE102004020186A1 (en) 2005-11-17
ATE386737T1 (en) 2008-03-15
CA2563401A1 (en) 2005-11-10
EP1864979B1 (en) 2011-09-07

Similar Documents

Publication Publication Date Title
HK1101823A1 (en) Imidazole derivatives used as tafia inhibitors
ZA200700181B (en) Aryl-pyridine derivatives as 11-beta-HSD1 inhibitors
ZA200702394B (en) Indozolone derivatives as 11b-HSD1 inhibitors
IL194582A0 (en) Condensed imidazole derivatives as aromatase inhibitors
HK1133650A1 (en) Hydantoin derivatives used as mmp inhibitors
IL198247A0 (en) Indazole derivatives useful as l-cpt1 inhibitors
EP1790650B1 (en) Novel substituted imidazole derivatives
HK1135391A1 (en) Triazole derivatives as kinase inhibitors
ZA200610771B (en) Quinazolinedolone derivatives as PARP inhibitors
IL193482A0 (en) Hydantoin based kinase inhibitors
PT1763517E (en) Pyrimidine derivatives as 11beta-hsd1 inhibitors
IL183599A0 (en) Novel hydantoin derivatives as metalloproteinase inhibitors
ZA200904175B (en) Imidazole derivatives as kinesin spindle protein inhibitors (EG-5)
IL183667A0 (en) Novel hydantoin derivatives as metalloproteinase inhibitors
HK1108435A1 (en) Hydantoin derivatives useful as metalloproteinase inhibitors
PL1937673T3 (en) Imidazole derivatives as inhibitors of tafia
SI2104497T1 (en) Sulfamide derivatives as tafia inhibitors
IL184559A0 (en) Imidazole derivatives
ZA200608998B (en) Imidazole derivatives as tyrosine kinase inhibitors
ZA200806993B (en) Hydantoin based kinase inhibitors

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees